The startup develops immunotherapies that utilize interferon epsilon to enhance immune responses against cancer by mimicking the body's natural defense mechanisms found in the female reproductive tract. This approach aims to reduce metastasis and provide patients with a novel treatment option for oncological conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many cancers evade the body's natural immune defenses, leading to uncontrolled growth and metastasis. Current cancer treatments often have significant side effects and may not be effective for all patients, highlighting the need for novel immunotherapeutic approaches.
Solution
The startup is developing a novel class of immunotherapies based on interferon epsilon (IFNe), a naturally occurring cytokine primarily found in the female reproductive tract. IFNe-based therapies aim to stimulate a robust and targeted immune response against cancer cells, potentially overcoming resistance mechanisms and reducing metastasis. By harnessing the unique properties of IFNe, the company seeks to create more effective and less toxic cancer treatments that can improve patient outcomes. The approach focuses on enhancing the body's own ability to recognize and eliminate cancer cells, offering a new strategy for combating oncological conditions.
Target Audience
The primary target audience includes patients with various types of cancer, as well as oncologists and researchers seeking innovative immunotherapeutic options.
Features
- IFNe-based immunotherapeutic agents designed to activate innate and adaptive immune responses
- Targeted delivery mechanisms to enhance IFNe activity within the tumor microenvironment
- Preclinical data demonstrating efficacy in reducing tumor growth and metastasis in various cancer models
- Proprietary formulations to optimize IFNe stability and bioavailability
- Potential for combination therapies with existing cancer treatments to enhance overall efficacy